Under-utilisation of cardioprotective glucose-lowering medication in diabetics living with HIV

Bakani Butale, Ian Woolley, Kathryn Cisera, Tony Korman, Georgia Soldatos

Research output: Contribution to journalLetterOtherpeer-review

2 Citations (Scopus)


Diabetes is an increasingly common co-morbidity in people living with HIV (PLWH). Given new evidence demonstrating cardiovascular benefits of sodium glucose transporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP1RA) in diabetic patients, we reviewed medical charts of 262 PLWH at Monash Health through a 1-year retrospective cohort study to determine the rates of their use. Prevalence of diabetes was 13.4% (35) and 60% (21) had microvascular and macrovascular complications. Only 4% (95% CI 0.1%-19.6%) of diabetic patients were receiving SGLT2i and 19% (95% CI 6%-39.4%) were receiving GLP1RA. Prescribers should carefully consider their choice of glucose-lowering medication when treating PLWH.

Original languageEnglish
Pages (from-to)580-582
Number of pages3
JournalSexual Health
Issue number6
Publication statusPublished - 2022


  • cardiovascular
  • diabetes
  • evidence-based medicine
  • GLP1RA
  • glucose-lowering medications
  • HIV co-morbidities
  • SLGT2i

Cite this